Pradžia › Išsėtinė sklerozė › Arizona
Išsėtinė sklerozė klinikiniai tyrimai Arizona
6 tyrimai dėl Išsėtinė sklerozė ieško dalyvių vietose Arizona.
Miestai Arizona
Oficialus tyrimo tekstas (anglų kalba)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Perseverance Research Center,LLC, Scottsdale
Renkami dalyviai2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06782490A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- Clinical Endpoints, LLC, Scottsdale
Renkami dalyviai4 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-30 · NCT07609719A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Gilbert
- TG Therapeutics Investigational Trial Site, Phoenix
- TG Therapeutics Investigational Trial Site, Scottsdale
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT06433752RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Arizona, Tucson
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-15 · NCT07002034Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Center for Neurology and Spine - Phoenix - East Bell Road- Site Number : 8400195, Phoenix
- Perseverance Research Center- Site Number : 8400138, Scottsdale
Renkami dalyviai3 fazė
Amžius nuo 18 iki 60 · Visoms lytims · Atnaujinta 2026-09-15 · NCT07325292A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Ctr for Neurology and Spine, Phoenix
- AZ Integrated Neuro and Spine, Phoenix
- Center for Neurosciences, Tucson
Renkami dalyviai3 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-07-29 · NCT07225504Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.